期刊
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT
卷 34, 期 1, 页码 469-474出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13102818.2020.1775118
关键词
Ivermectin; SARS-CoV-2; COVID-19; drug repurposing
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the present report the in vitro antiviral activity end-points are analyzed from the pharmacokinetic perspective. The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据